Division of Gastroenterology & Hepatology Research
Our research goals at NYU Langone’s Division of Gastroenterology and Hepatology are to provide access to the latest treatments in the pipeline to our patients and to advance knowledge of gastroenterology and hepatology through innovative basic science, translational research, and clinical trials. We aim to foster a spirit of scientific inquiry and innovation among faculty, fellows, and students.
Our researchers study the biology, prevention, diagnosis, and treatment of gastrointestinal (GI) and liver diseases. Among our current areas of research are the following:
- role of the gut microbiome in health and the pathogenesis of disease such as colorectal cancer, liver cancer, and fatty liver and other diseases
- role of GI infection and gut microbial dysbiosis in the pathogenesis of inflammatory bowel disease
- quality and innovations in enhanced technologies for colon cancer screening
- bariatric endoscopy outcomes in obesity and fatty liver disease
- clinical trials in all areas of liver disease, inflammatory bowel disease, colorectal cancer screening and prevention, and other GI conditions
- cirrhosis and hepatitis C infection
Select Faculty Publications
Impact of offering blood-based testing alongside existing modalities for colorectal cancer screening among those who previously declined screening: an economic evaluation
Journal of medical economics. 2026 Dec ; 29:609-619
Interventions for Increasing Colorectal Cancer Screening Uptake: A Systematic Review and Network Meta-Analysis
Gastroenterology. 2026 Apr 01;
Quality indicators of endoscopists for both index and surveillance colonoscopy are associated with risk of Metachronous Colorectal Neoplasia
Clinical and translational gastroenterology. 2026 Apr 01;
Reply: Cost-effectiveness of Novel Noninvasive Screening Tests for Colorectal Neoplasia [Letter]
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2026 Mar 27;
Development and Validation of a Parsimonious Risk Stratification Model for Pancreatic Cancer
JAMA oncology. 2026 Mar 26;
Expert Practical Recommendations for Hepatocellular Carcinoma
Seminars in liver disease. 2026 Mar 25;
AVB-114 Demonstrates Clinical Benefit in Persistent Crohn's Perianal Fistulas: Randomized Cohort Results from the Multicenter STOMP2 Trial
The American journal of gastroenterology. 2026 Mar 25;
Defining Moderate Disease Activity and Severity in Crohn's Disease and Ulcerative Colitis
Journal of clinical gastroenterology. 2026 Mar 24;